https://www.ascopost.com/videos/esmo-congress-2022/marleen-kok-on-triple-negative-breast-cancer-nivolumab-monotherapy-or-in-combination-therapy/
https://ascopost.com/videos/esmo-congress-2022/marleen-kok-on-triple-negative-breast-cancer-nivolumab-monotherapy-or-in-combination-therapy/
https://www.ascopost.com/issues/september-25-2022/practice-changing-studies-important-new-data-and-more-clinical-oncology-news-from-esmo-2022-paris/
https://ascopost.com/issues/september-25-2022/practice-changing-studies-important-new-data-and-more-clinical-oncology-news-from-esmo-2022-paris/
https://www.ascopost.com/issues/september-25-2022/epov-corinne-faivre-finn-and-masahiro-tsuboi/
https://ascopost.com/issues/september-25-2022/epov-corinne-faivre-finn-and-masahiro-tsuboi/
https://www.ascopost.com/issues/september-25-2022/nadim-trial-neoadjuvant-chemoimmunotherapy-improved-survival-in-resectable-stage-iiia-nsclc/
https://ascopost.com/issues/september-25-2022/nadim-trial-neoadjuvant-chemoimmunotherapy-improved-survival-in-resectable-stage-iiia-nsclc/
https://www.ascopost.com/videos/esmo-congress-2022/nizar-tannir-on-rcc-data-on-bempegaldesleukin-plus-nivolumab-vs-tyrosine-kinase-inhibitors-in-untreated-disease/
https://ascopost.com/videos/esmo-congress-2022/nizar-tannir-on-rcc-data-on-bempegaldesleukin-plus-nivolumab-vs-tyrosine-kinase-inhibitors-in-untreated-disease/
https://www.ascopost.com/news/september-2022/adjuvant-nivolumab-with-or-without-ipilimumab-in-patients-with-resected-stage-iv-melanoma-with-no-evidence-of-disease/
https://ascopost.com/news/september-2022/adjuvant-nivolumab-with-or-without-ipilimumab-in-patients-with-resected-stage-iv-melanoma-with-no-evidence-of-disease/
https://www.ascopost.com/news/september-2022/sequencing-of-ipilimumabnivolumab-with-encorafenibbinimetinib-in-braf-mutant-metastatic-melanoma/
https://ascopost.com/news/september-2022/sequencing-of-ipilimumabnivolumab-with-encorafenibbinimetinib-in-braf-mutant-metastatic-melanoma/
https://www.ascopost.com/videos/esmo-congress-2022/gerard-zalcman-on-non-small-cell-lung-cancer-phase-iii-trial-findings-on-nivolumab-and-ipilimumab/
https://ascopost.com/videos/esmo-congress-2022/gerard-zalcman-on-non-small-cell-lung-cancer-phase-iii-trial-findings-on-nivolumab-and-ipilimumab/
https://www.ascopost.com/news/september-2022/dual-checkpoint-inhibitor-blockade-as-first-line-and-salvage-therapy-for-patients-with-advanced-merkel-cell-carcinoma/
https://ascopost.com/news/september-2022/dual-checkpoint-inhibitor-blockade-as-first-line-and-salvage-therapy-for-patients-with-advanced-merkel-cell-carcinoma/
https://www.ascopost.com/news/september-2022/early-research-identifies-effective-combination-immunotherapy-for-subgroup-of-patients-with-metastatic-colorectal-cancer/
https://ascopost.com/news/september-2022/early-research-identifies-effective-combination-immunotherapy-for-subgroup-of-patients-with-metastatic-colorectal-cancer/
https://www.ascopost.com/videos/esmo-congress-2022/rcc-recent-phase-iii-data-on-cabozantinib-nivolumab-and-ipilimumab-from-the-cosmic-313-trial/
https://ascopost.com/videos/esmo-congress-2022/rcc-recent-phase-iii-data-on-cabozantinib-nivolumab-and-ipilimumab-from-the-cosmic-313-trial/
https://www.ascopost.com/videos/esmo-congress-2022/martin-reck-md-phd-on-nsclc-new-findings-on-cemiplimab-nivolumab-and-ipilimumab/
https://ascopost.com/videos/esmo-congress-2022/martin-reck-md-phd-on-nsclc-new-findings-on-cemiplimab-nivolumab-and-ipilimumab/
https://www.ascopost.com/videos/esmo-congress-2022/ana-oaknin-on-cervical-cancer-safety-and-efficacy-results-with-nivolumab-and-ipilimumab/
https://ascopost.com/videos/esmo-congress-2022/ana-oaknin-on-cervical-cancer-safety-and-efficacy-results-with-nivolumab-and-ipilimumab/
https://www.ascopost.com/news/september-2022/m14til-tumor-infiltrating-lymphocytes-for-patients-with-advanced-melanoma/
https://ascopost.com/news/september-2022/m14til-tumor-infiltrating-lymphocytes-for-patients-with-advanced-melanoma/
https://www.ascopost.com/news/september-2022/cosmic-313-cabozantinib-nivolumab-and-ipilimumab-in-previously-untreated-patients-with-advanced-renal-cell-carcinoma/
https://ascopost.com/news/september-2022/cosmic-313-cabozantinib-nivolumab-and-ipilimumab-in-previously-untreated-patients-with-advanced-renal-cell-carcinoma/
https://www.ascopost.com/news/september-2022/prosper-rcc-neoadjuvant-nivolumab-prior-to-nephrectomy-followed-by-additional-nivolumab-in-patients-with-renal-cell-carcinoma/
https://ascopost.com/news/september-2022/prosper-rcc-neoadjuvant-nivolumab-prior-to-nephrectomy-followed-by-additional-nivolumab-in-patients-with-renal-cell-carcinoma/
https://www.ascopost.com/news/september-2022/addition-of-telaglenastat-to-cabozantinib-in-previously-treated-patients-with-metastatic-renal-cell-carcinoma/
https://ascopost.com/news/september-2022/addition-of-telaglenastat-to-cabozantinib-in-previously-treated-patients-with-metastatic-renal-cell-carcinoma/
https://www.ascopost.com/news/august-2022/neoadjuvant-nivolumab-plus-ipilimumab-in-localized-dmmrmsi-h-gastric-cancer/
https://ascopost.com/news/august-2022/neoadjuvant-nivolumab-plus-ipilimumab-in-localized-dmmrmsi-h-gastric-cancer/
https://www.ascopost.com/issues/august-25-2022/new-guideline-updates-address-stage-iv-non-small-cell-lung-cancer-with-and-without-driver-alterations/
https://ascopost.com/issues/august-25-2022/new-guideline-updates-address-stage-iv-non-small-cell-lung-cancer-with-and-without-driver-alterations/
https://www.ascopost.com/issues/august-10-2022/asco-releases-first-comprehensive-evidence-based-guidelines-for-metastatic-clear-cell-rcc/
https://ascopost.com/issues/august-10-2022/asco-releases-first-comprehensive-evidence-based-guidelines-for-metastatic-clear-cell-rcc/
https://www.ascopost.com/issues/august-10-2022/epov-rebecca-dent/
https://ascopost.com/issues/august-10-2022/epov-rebecca-dent/
https://www.ascopost.com/issues/august-10-2022/nivolumab-plus-t-dxd-under-study-in-her2-expressing-metastatic-breast-cancer/
https://ascopost.com/issues/august-10-2022/nivolumab-plus-t-dxd-under-study-in-her2-expressing-metastatic-breast-cancer/
https://www.ascopost.com/issues/august-10-2022/immunotherapy-for-gastrointestinal-malignancies-is-it-ready-for-prime-time/
https://ascopost.com/issues/august-10-2022/immunotherapy-for-gastrointestinal-malignancies-is-it-ready-for-prime-time/
https://www.ascopost.com/videos/2022-asco-annual-meeting/rami-manochakian-on-nsclc-clinical-implications-of-findings-on-nivolumab-plus-chemotherapy/
https://ascopost.com/videos/2022-asco-annual-meeting/rami-manochakian-on-nsclc-clinical-implications-of-findings-on-nivolumab-plus-chemotherapy/
https://www.ascopost.com/issues/august-10-2022/epov-alison-moskowitz/
https://ascopost.com/issues/august-10-2022/epov-alison-moskowitz/
https://www.ascopost.com/news/july-2022/noncytotoxic-maintenance-with-niraparib-plus-either-nivolumab-or-ipilimumab-in-platinum-sensitive-advanced-pancreatic-cancer/
https://ascopost.com/news/july-2022/noncytotoxic-maintenance-with-niraparib-plus-either-nivolumab-or-ipilimumab-in-platinum-sensitive-advanced-pancreatic-cancer/
https://www.ascopost.com/issues/july-25-2022/deciphering-the-elusive-origin-and-pathways-of-brain-metastases/
https://ascopost.com/issues/july-25-2022/deciphering-the-elusive-origin-and-pathways-of-brain-metastases/
https://www.ascopost.com/news/july-2022/addition-of-brentuximab-vedotin-to-chemotherapy-in-patients-with-stage-iii-or-iv-hodgkin-lymphoma-overall-survival-analysis-from-echelon-1/
https://ascopost.com/news/july-2022/addition-of-brentuximab-vedotin-to-chemotherapy-in-patients-with-stage-iii-or-iv-hodgkin-lymphoma-overall-survival-analysis-from-echelon-1/
https://www.ascopost.com/news/july-2022/immune-checkpoint-inhibitors-for-solid-tumors-in-kidney-transplant-recipients-with-maintained-immunosuppression/
https://ascopost.com/news/july-2022/immune-checkpoint-inhibitors-for-solid-tumors-in-kidney-transplant-recipients-with-maintained-immunosuppression/
https://www.ascopost.com/news/july-2022/trastuzumab-and-nivolumab-plus-either-ipilimumab-or-folfox-as-first-line-treatment-for-her2-positive-advanced-esophagogastric-adenocarcinoma/
https://ascopost.com/news/july-2022/trastuzumab-and-nivolumab-plus-either-ipilimumab-or-folfox-as-first-line-treatment-for-her2-positive-advanced-esophagogastric-adenocarcinoma/
https://www.ascopost.com/issues/june-25-2022/immunotherapy-has-given-me-back-my-life/
https://ascopost.com/issues/june-25-2022/immunotherapy-has-given-me-back-my-life/
https://www.ascopost.com/issues/june-25-2022/nivolumab-in-combination-with-chemotherapy-and-in-combination-with-ipilimumab-in-advanced-esophageal-squamous-cell-carcinoma/
https://ascopost.com/issues/june-25-2022/nivolumab-in-combination-with-chemotherapy-and-in-combination-with-ipilimumab-in-advanced-esophageal-squamous-cell-carcinoma/
https://www.ascopost.com/news/june-2022/nivolumabcabozantinib-vs-sunitinib-in-first-line-treatment-for-advanced-rcc-overall-survival-analysis-of-checkmate-9er-trial/
https://ascopost.com/news/june-2022/nivolumabcabozantinib-vs-sunitinib-in-first-line-treatment-for-advanced-rcc-overall-survival-analysis-of-checkmate-9er-trial/
https://www.ascopost.com/issues/june-25-2022/notable-trial-survival-in-pancreatic-kras-wild-type-cancer-improved-with-addition-of-nimotuzumab-to-gemcitabine/
https://ascopost.com/issues/june-25-2022/notable-trial-survival-in-pancreatic-kras-wild-type-cancer-improved-with-addition-of-nimotuzumab-to-gemcitabine/
https://www.ascopost.com/issues/june-25-2022/epov-kimmie-ng/
https://ascopost.com/issues/june-25-2022/epov-kimmie-ng/
https://www.ascopost.com/issues/june-25-2022/epov-guru-sonpavde/
https://ascopost.com/issues/june-25-2022/epov-guru-sonpavde/
https://www.ascopost.com/news/june-2022/checkmate-274-adjuvant-immunotherapy-improves-disease-free-survival-in-metastatic-urothelial-cancer/
https://ascopost.com/news/june-2022/checkmate-274-adjuvant-immunotherapy-improves-disease-free-survival-in-metastatic-urothelial-cancer/
https://www.ascopost.com/video-roundtable/updates-in-lymphoma/relapsedrefractory-hodgkin-lymphoma/
https://ascopost.com/video-roundtable/updates-in-lymphoma/relapsedrefractory-hodgkin-lymphoma/
https://www.ascopost.com/news/june-2022/three-arm-first-line-chemoimmunotherapy-study-in-patients-with-metastatic-pancreatic-cancer/
https://ascopost.com/news/june-2022/three-arm-first-line-chemoimmunotherapy-study-in-patients-with-metastatic-pancreatic-cancer/
https://www.ascopost.com/news/june-2022/neoadjuvant-immunotherapy-may-improve-survival-for-patients-with-soft-tissue-sarcoma/
https://ascopost.com/news/june-2022/neoadjuvant-immunotherapy-may-improve-survival-for-patients-with-soft-tissue-sarcoma/
https://www.ascopost.com/issues/june-3-2022-narratives-special-issue/new-fda-approved-oncology-drugs-2021-2022/
https://ascopost.com/issues/june-3-2022-narratives-special-issue/new-fda-approved-oncology-drugs-2021-2022/
https://www.ascopost.com/issues/june-10-2022/fda-approves-two-nivolumab-based-regimens-as-first-line-treatments-for-unresectable-advanced-or-metastatic-esophageal-squamous-cell-carcinoma/
https://ascopost.com/issues/june-10-2022/fda-approves-two-nivolumab-based-regimens-as-first-line-treatments-for-unresectable-advanced-or-metastatic-esophageal-squamous-cell-carcinoma/
https://www.ascopost.com/news/may-2022/neoadjuvant-nivolumab-plus-chemotherapy-in-resectable-stage-iiia-nsclc-overall-survival-and-biomarker-analyses/
https://ascopost.com/news/may-2022/neoadjuvant-nivolumab-plus-chemotherapy-in-resectable-stage-iiia-nsclc-overall-survival-and-biomarker-analyses/
https://www.ascopost.com/issues/may-25-2022/checkmate-816-neoadjuvant-nivolumab-plus-chemotherapy-improves-event-free-survival-over-chemotherapy-alone-in-resectable-nsclc/
https://ascopost.com/issues/may-25-2022/checkmate-816-neoadjuvant-nivolumab-plus-chemotherapy-improves-event-free-survival-over-chemotherapy-alone-in-resectable-nsclc/
https://www.ascopost.com/issues/may-25-2022/pd-1-inhibition-in-first-line-treatment-of-advanced-esophageal-squamous-cell-carcinoma-more-to-come-on-new-paradigm/
https://ascopost.com/issues/may-25-2022/pd-1-inhibition-in-first-line-treatment-of-advanced-esophageal-squamous-cell-carcinoma-more-to-come-on-new-paradigm/
https://www.ascopost.com/issues/may-25-2022/overall-survival-benefit-with-nivolumab-plus-chemotherapy-or-ipilimumab-vs-chemotherapy-alone-in-esophageal-squamous-cell-carcinoma/
https://ascopost.com/issues/may-25-2022/overall-survival-benefit-with-nivolumab-plus-chemotherapy-or-ipilimumab-vs-chemotherapy-alone-in-esophageal-squamous-cell-carcinoma/
https://www.ascopost.com/issues/may-25-2022/epov-edward-garon/
https://ascopost.com/issues/may-25-2022/epov-edward-garon/
https://www.ascopost.com/issues/may-25-2022/novel-neoadjuvant-therapy-may-boost-response-in-resectable-nsclc/
https://ascopost.com/issues/may-25-2022/novel-neoadjuvant-therapy-may-boost-response-in-resectable-nsclc/
https://www.ascopost.com/issues/may-25-2022/epov-mario-sznol-and-stefania-scala/
https://ascopost.com/issues/may-25-2022/epov-mario-sznol-and-stefania-scala/
https://www.ascopost.com/issues/may-25-2022/approaches-to-potentiate-immune-response-in-patients-who-do-not-respond-to-anti-pd-1-therapy-for-melanoma/
https://ascopost.com/issues/may-25-2022/approaches-to-potentiate-immune-response-in-patients-who-do-not-respond-to-anti-pd-1-therapy-for-melanoma/